ASSESSMENT OF CARDIAC FUNCTION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB AT THE NATIONAL CENTER OF HEMATOLOGY

YASSEN MOHI ALDEEN  TAHER; ADEEB ABBAS AHMED  ALSHAMI; HAYDER ADNAN  FAWZI; NADHIM  SHALAAN; ALAA FADHIL  ALWAN

doi:10.22159/ajpcr.2018.v11i10.27059

Authors

YASSEN MOHI ALDEEN TAHER Department of Medicine, Al Iraqi University, College of Medicine, Iraq.
ADEEB ABBAS AHMED ALSHAMI Department of Internal Medicine, The National Center of Hematology, Mustansiriyah University, Iraq.
HAYDER ADNAN FAWZI Department of Clinical Pharmacy, Medical City Complex, Baghdad Teaching Hospital, Iraq. http://orcid.org/0000-0001-9970-0119
NADHIM SHALAAN Department of Cardiology Al-Yarmouk Teaching Hospital, Baghdad, Iraq.
ALAA FADHIL ALWAN Department of Haematology, The National Center of Hematology, Mustansiriyah University, Iraq.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i10.27059

Keywords:

Imatinib, Cardiotoxicity, Echocardiology, Chronic myeloid leukemia

Abstract

Objective: The objective was to study the assessment of the possible cardiotoxic effect of imatinib using echocardiography.

Methods: Prospective study included 50 patients that treated at the National Hematology Center of Al-Mustansiriya University from May 2008 to December 2009, echocardiography was used to measure the cardiac ejection fraction accurately, indices of ventricular ejection and relaxation and measurement of left ventricular internal diameter in diastole and (LVIDd) at baseline and after 12 months.

Results: 24 (41%) were men and 26 (59%) were women. Their ages ranged from 18 to 74 years, with a median age of 36.8 years. At baseline, mean EF was 0.63Â±0.057 and after 12 months; mean EF was 0.64Â±0.068 (p>0.05). Mean peak emptying rate at baseline was 3.23Â±0.5 ED/s, and after 1 year was 3.21Â±0.5 ED/s (p>0.05). Time to peak filling rate at baseline was 144Â±26 ms, and after 1 year was 143Â±25 ms (p>0.05). There is a significant inverse trend for both LVIDd and LVID in systole (LVIDs) reduced as age increase; the female had significantly lower LVIDd and LVIDs compared to male.

Conclusion: We find no evidence of significant impairment in cardiac function over 12 months of imatinib treatment. Advancing age associated with reduced cardiac performance for patients receiving imatinib.

Downloads

Download data is not yet available.

Author Biographies

YASSEN MOHI ALDEEN TAHER, Department of Medicine, Al Iraqi University, College of Medicine, Iraq.

FICMS (haematology)

ADEEB ABBAS AHMED ALSHAMI, Department of Internal Medicine, The National Center of Hematology, Mustansiriyah University, Iraq.

FICMS

HAYDER ADNAN FAWZI, Department of Clinical Pharmacy, Medical City Complex, Baghdad Teaching Hospital, Iraq.

Clinical Pharmacy Board

Clinical Research

NADHIM SHALAAN, Department of Cardiology Al-Yarmouk Teaching Hospital, Baghdad, Iraq.

FICMS

ALAA FADHIL ALWAN, Department of Haematology, The National Center of Hematology, Mustansiriyah University, Iraq.

FICMS (hematology)

References

Deininger M, Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:1126.

Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study. J Clin Oncol 2003;21:2138-46.

Gupta M, Dahiya J, Marwaha RK, Dureja H. Therapies in cancer treatment: An overview. Int J Pharm Pharm Sci 2015;7:1-9.

Darji AA, Bharadia PD. Chronic myelogenous leukemia: A review and update of current and future therapy. Int J Pharm Pharm Sci 2016;8:35-46.

Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16.

Force T. In reply to cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2007;13:15.

Druker BJ, Guilhot F, Oâ€™Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 2006;355:2408-17.

Hochhaus A, Druker BJ, Larson RA, Oâ€™Brien SG, Gathmann I, Guilhot F. IRIS 6-Year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2007;110:25.

Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007;109:5143-50.

Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-7.

Freebern WJ, Fang HS, Slade MD, Wells S, Canale J, Megill J, et al. In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: Dasatinib, imatinib and nilotinib. Blood 2007;110:4582.

Francisco ARG, Alves D, David C, Guerra L, Pinto FJ, Almeida AG, et al. Cardiotoxicity in hematological diseases: Are the tyrosine kinase inhibitors imatinib and nilotinib safe? Cardiovasc Toxicol 2018;doi: 10.1007/s12012-018-9453-3.

Maharsy W, Aries A, Mansour O, Komati H, Nemer M. Ageing is a risk factor in imatinib mesylate cardiotoxicity. Eur J Heart Fail 2014;16:367-76.